SCHEMBL1644569

SCHEMBL1644569

Cc1ccnc(N2CCN(c3ccc(NC(=O)C(=O)c4c(-c5ccccc5)cc5ccc(C)cn45)cc3)CC2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.43
ALDH1A1 P00352 5/20 0.43
LMNA P02545 3/20 0.43
HTT P42858 2/20 0.43
KDM4E B2RXH2 3/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
DRD2 P14416 1/20 0.38
DRD4 P21917 1/20 0.38
DRD3 P35462 1/20 0.38
GLA P06280 1/20 0.38
THRB P10828 1/20 0.38
CHRNA7 P36544 1/20 0.37
GAA P10253 2/20 0.37
KDM5B Q9UGL1 1/20 0.37
MAPK10 P53779 3/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2230725 0.93 ALDH1A1 (0.42) MAPTALDH1A1LMNAHTTKDM4E
SCHEMBL2231057 0.93 ALDH1A1 (0.43) MAPTALDH1A1LMNAHTTKDM4E
SCHEMBL1647623 0.92 ALDH1A1 (0.48) MAPTALDH1A1LMNAHTTKDM4E
SCHEMBL1646592 0.91 SLC1A2 (0.42) MAPTALDH1A1LMNAHTTKDM4E
SCHEMBL1647296 0.91 ALDH1A1 (0.53) MAPTALDH1A1LMNAHTTKDM4E
SCHEMBL2230684 0.89 ALDH1A1 (0.46) MAPTALDH1A1LMNAHTTKDM4E
SCHEMBL1647616 0.89 MAPT (0.51) MAPTALDH1A1LMNAHTTKDM4E
SCHEMBL1646659 0.88 MAPT (0.43) MAPTALDH1A1LMNAHTTKDM4E
SCHEMBL2232509 0.87 MAPT (0.43) MAPTALDH1A1LMNAHTTNPC1
SCHEMBL1646439 0.86 MAPT (0.42) MAPTALDH1A1LMNAHTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097413-B1 2-[(2-SUBSTITUTED)-IND0LIZIN-3-YL]-2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS F2G LTD (GB) 2013-12-25 EP disclosed
CN-101679410-B 2-[(2-substituted)-ind0lizin-3-yl]-2-oxo-acetamide derivatives as antifungal agents F2G LTD 2013-11-27 CN disclosed
US-20110183969-A1 ANTIFUNGAL COMBINATION THERAPY F2G LTD (GB) 2011-07-28 US disclosed
CN-102105170-A Antifungal combination therapy F2G LTD 2011-06-22 CN disclosed
EP-2303329-A1 ANTIFUNGAL COMBINATION THERAPY F2G Limited (GB) 2011-04-06 EP disclosed
CN-101679410-A 2-[(2-substituted)-ind0lizin-3-yl]-2-oxo-acetamide derivatives as antifungal agents F2G LTD 2010-03-24 CN disclosed
WO-2009144473-A1 ANTIFUNGAL COMBINATION THERAPY F2G LIMITED (GB) 2009-12-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110183969-A1 ANTIFUNGAL COMBINATION THERAPY IDO1, FOXM1, IPO5 MAPT 1771/4885ALDH1A1 2813/4885LMNA 3870/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.